Trial Profile
Phase I study of HM 12525A in patients with obesity
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 28 May 2014
Price :
$35
*
At a glance
- Drugs Efinopegdutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- 16 May 2014 40 subjects with obesity will receive a single injection, according to a Hanmi Pharmaceuticals media release.
- 10 Jul 2013 New trial record